A pilot study testing the feasibility of a single microdose of ayahuasca alkaloids on neurotransmitters, inflammation marker levels, safety, and mood in healthy adult volunteers

Single-group, open-label, non-randomised pilot in healthy volunteers assessing a single morning oral microdose of ayahuasca alkaloids (30 mg) co-administered with an l‑epicatechin cyclodextrin complex; biological samples collected at baseline and 1.5 hours post-dose.

Primary measures include blood cholinesterase and IL-6 at baseline and 1.5 hours post-intervention, along with safety observations and mood/self-efficacy assessments.